Company news
Verrica Pharmaceuticals Inc. news in 2026
Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2026, newest first.
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
November 12, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
November 10, 2026
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
November 5, 2026
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
October 22, 2026
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
September 30, 2026
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
September 10, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
August 27, 2026
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 6, 2026
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
August 6, 2026
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
July 21, 2026
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
June 21, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 28, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
May 12, 2026
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 5, 2026
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
May 5, 2026
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
April 8, 2026
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 10, 2026
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
March 5, 2026
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
February 12, 2026
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
February 9, 2026
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
January 7, 2026
Calls in 2026
- Verrica Pharmaceuticals (NASDAQ:VRCA) Q3 2026 Earnings Call
Nov 12, 2026
Transcript - Verrica Pharmaceuticals (NASDAQ:VRCA) Q2 2026 Earnings Call
Aug 6, 2026
Transcript - Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 2026 Earnings Call
May 12, 2026
Transcript - Verrica Pharmaceuticals (NASDAQ:VRCA) Q4 2025 Earnings Call
Mar 11, 2026
Transcript
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 22 slides · September 2026